Yifan Xie

Dr. Yifan Xie

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2026 in European Journal of Preventive Cardiology
Verified
Journal Article
Open access
Yifan XieYifan Xie
Yifan Xie
WLWenhui Li
Wenhui Li
YMYanda Meng
Yanda Meng
THTianjin Huang
Tianjin Huang
YZYalin Zheng
Yalin Zheng
Gregory LipGregory Lip
Gregory Lip
Aims: Major bleeding remains a major barrier to optimal anticoagulation in patients with atrial fibrillation (AF). We aimed to develop and externally validate a weighted score that balances clinical usability and predictive performance for 1-year major bleeding prediction. Methods and results: Using prospective multinational Global Registry on Long-Term Oral Antithrombotic Treatment in Patients With Atrial Fibrillation (GLORIA-AF) Phase II/III data, we developed the GLORIA-AF Bleeding Weighted Risk Score using least absolute shrinkage and selection operator-penalized regression with stability selection, coefficient rescaling, and internal validation. The score was externally evaluated in EURObservational Research Programme Atrial Fibrillation and EURObservational Research Programme Atrial Fibrillation registries. Discrimination, calibration, and clinical benefit were assessed using concordance index (C-index), observed-to-expected ratio, calibration plot, and decision-curve analysis and compared with HAS-BLED, the unweighted GLORIA-AF score, and the full multivariable Cox model. Among 20 250 eligible derivation cohort patients [69.9 (10.3) years; 9092 female (44.9%)], 317 (1.6%) had major bleeding during 1-year follow-up. The derived score ranges from 0 to 22, with the highest weight (5) assigned to age >65 years, followed by abnormal kidney function (3). The derived score achieved a C-index of 0.688 (95% CI, 0.660–0.717), outperforming HAS-BLED (C-index, 0.631; 95% CI, 0.604–0.658; P < 0.001), while preserving discrimination comparable to full multivariable regression (C-index, 0.690; 95% CI, 0.661–0.719; P = 0.084). Calibration was good (observed-to-expected ratio, 0.996) and DCA showed a greater net benefit than HAS-BLED across 1–3% thresholds. Among 9752 external validation patients, 148 (1.5%) had major bleeding. The derived score achieved a C-index of 0.674 (95% CI, 0.643–0.705; P < 0.001), with better discrimination, calibration, and clinical benefit than HAS-BLED. Conclusion: The GLORIA-AF Bleeding Score showed modestly higher discrimination than HAS-BLED for 1-year major bleeding prediction while retaining clinical interpretability and usability. External validation in independent European and Asia-Pacific registries further supports its transportability beyond the derivation population.

29 August 2026 in EP Europace
Verified
Journal Article
Open access
Yifan XieYifan Xie
Yifan Xie
WLWenhui Li
Wenhui Li
YMYanda Meng
Yanda Meng
THTianjin Huang
Tianjin Huang
Yalin ZhengYalin Zheng
Yalin Zheng
Gregory LipGregory Lip
Gregory Lip
Aims: Accurate stroke risk stratification is central to anticoagulation decision-making in patients with atrial fibrillation (AF), but conventional scores may not fully capture risk heterogeneity. We aimed to develop and externally validate an interpretable weighted score using a time-to-event framework. Methods and results: GLORIA-AF Phase II/III data were used to evaluate 17 baseline predictors using LASSO-penalized Cox regression with stability selection; coefficients were converted into integer weights. Performance was assessed using discrimination, calibration, integrated discrimination improvement (IDI), continuous net reclassification improvement (NRI), and decision curve analysis. External validation was performed in EORP-AF and APHRS-AF registries. Among 20 517 patients included in the derivation cohort [mean (SD) age, 69.9 (10.3) years; 9196 women (44.8%)], 487 (2.4%) had stroke, and 17 397 (84.8%) were receiving anticoagulation at baseline. Ten selected predictors formed a 0–23-point score. The derived score achieved a C-index of 0.661 (95% CI, 0.636–0.685), higher than CHA2DS2-VA (0.626; P < 0.001), CHA2DS2-VASc (0.615; P < 0.001), and the unweighted score (P = 0.016), with no significant difference from the full Cox or machine learning models. In external validation (8309 patients; 147 strokes), the C-index was 0.652 (95% CI, 0.614–0.690) vs. 0.616 for CHA2DS2-VA (95% CI, 0.598–0.634; P < 0.001). IDI/NRI, calibration, and decision curve analyses supported improved risk differentiation, close calibration, and generally greater net benefit than CHA2DS2-VA. The score retained higher discrimination than CHA2DS2-VA among patients without baseline anticoagulation (P < 0.001). Conclusion: The GLORIA-AF Stroke Weighted Risk Score provides risk refinement beyond CHA2DS2-VA while retaining discrimination consistent with more complex models. External validation supports its transportability and potential adjunctive role in guideline-directed thromboembolic risk assessment.

Verified
Journal Article
Open access
PDF file
QGQiumei Gu
Qiumei Gu
HLHongyi Liu
Hongyi Liu
Yifan XieYifan Xie
Yifan Xie
FLFang Lu
Fang Lu
ZHZiyan He
Ziyan He
SJShuang xiao Jiang
Shuang xiao Jiang
Background/Objectives: A substantial proportion of eyes with exudative macular diseases show a suboptimal response to standard-dose anti-vascular endothelial growth factor (anti-VEGF) therapy, and evidence regarding clinical outcomes after same-agent double-dose escalation remains limited. We evaluated the functional and anatomical outcomes of same-agent double-dose anti-VEGF therapy in such eyes. Methods: In this observational real-world cohort study, we retrospectively reviewed eyes with exudative macular diseases that were switched to same-agent double-dose anti-VEGF therapy because of a suboptimal response to prior standard-dose treatment. Eligibility required clinician-assessed persistent or recurrent exudative activity during the standard-dose treatment course despite at least three prior anti-VEGF injections, based on the longitudinal treatment and imaging history. Insufficient visual response and inadequate durability were considered additional, potentially overlapping features supporting dose escalation. Primary outcomes were functional and anatomical changes after switching. Secondary outcomes included injection interval, time-to-event outcomes, and associated baseline factors. Results: A total of 104 patients (111 eyes) were included. Mixed-effects modeling showed a small longitudinal improvement in BCVA of 0.007 logMAR per month (p = 0.028) and an estimated CST decrease of approximately 2.1% per month (p < 0.001). In visit-specific analyses, BCVA did not differ significantly from baseline at the first three post-switch visits and differed significantly only at the final follow-up (p = 0.004); however, the median BCVA was 0.70 logMAR at both baseline and final follow-up, and the median within-eye change was 0.00 logMAR (IQR, −0.25 to 0.10). CST was significantly lower than baseline at all post-switch visits (all p < 0.01). Among the 73 eyes with calculable paired interval data, injection intervals did not differ significantly between the standard-dose and double-dose phases (p = 0.289). Baseline pigment epithelial detachment was associated with a less favorable BCVA change (p = 0.002), and worse baseline visual acuity was associated with a higher risk of subretinal fibrosis (hazard ratio, 2.854; p = 0.002). Conclusions: In this uncontrolled pre–post cohort, anatomical changes after same-agent double-dose escalation were more consistent than functional changes. The BCVA change was statistically detectable but small in magnitude and of uncertain clinical relevance. No significant interval extension was observed among the 73 eyes with complete paired interval data during the relatively short follow-up.